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Abstract 
Background: This study aimed to determine the effects of mitochondrial dysfunction 
on energy metabolism of granulosa cells (GCs) and the competence of oocytes in 
polycystic ovary syndrome (PCOS).  
Material and methods: A total of 158 patients who underwent controlled ovarian 
hyperstimulation (COH) were enrolled. The clinical outcomes of patients with and 
without PCOS under in vitro fertilisation-embryo transfer (IVF-ET) were compared. 
Human primary GCs were exposed to mitochondrial and glycolysis inhibitors. Then, 
the related indicators of mitochondrial activity and glycometabolism were compared 
with controls. The viability of GCs after mitochondrial inhibitors was also 
determined. 
Results: In PCOS patients, the number of retrieved oocytes significantly increased, 
but the high-quality embryos, available embryos, and high-quality blastocyst 
formation obviously decreased (p < 0.05). Furthermore, the mitochondrial membrane 
potential, adenosine triphosphate (ATP) content, mitochondrial DNA (mtDNA) copy 
number, and HIF-1α mRNA and protein levels in GCs decreased, while the levels of 
reactive oxygen species increased (p < 0.05). Mitochondrial inhibitors reduced the 
mitochondrial function, but increased the HIF-1α, GLUT1, LDHA, and PFKP gene 
expression. Glucose consumption gradually increased at 24, 48, and 72 hours of GC 
culture after CCCP treatment, and the viability of cells tested by CCK-8 increased (p 
< 0.05).  
Conclusion: GCs are dependent on mitochondrial respiration and glycolysis for 
energy provision. Mitochondrial dysfunction accompanied by abnormal glycolysis 
was observed in PCOS patients, which affects the switch of energy from metabolic to 
glycolytic. The failure of transformation to glycolysis and low HIF-1α expression in 
GCs during the development of follicles might be correlated with the low oocyte 
competence of PCOS. 
Keywords: polycystic ovary syndrome; granulosa cells; glycolysis; mitochondrial 
functions; hypoxia inducible factor-1α 
 
Introduction 
 Polycystic ovary syndrome (PCOS) is one of the most common female endocrine 
and metabolic disorders, which affects approximately 5–10% women at the 
reproductive age [1, 2]. It is highly heterogeneously characterised by 
hyperandrogenism, polycystic ovaries, and chronic anovulation, and it is attributed to 
three in four ovulatory infertilities [3]. Meanwhile, oocytes collected from PCOS 
patients who underwent in vitro fertilisation (IVF) are often of poor quality [4], 
leading to a high cancelation rate and low fertilisation rate [5, 6]. Several factors are 
known to affect oocyte quality and subsequent embryo development, such as nutrition, 
hormonal regulation, and environmental influence [7]. However, the pathophysiology 
of the poor oocyte quality of PCOS remains not fully understood. 
 Recent research suggests that disordered follicular development may be the core 
of the abnormalities that occur in the ovary in PCOS [8]. During follicle growth, 
granulosa cells (GCs) surrounding the oocytes play an active role in oocyte 
differentiation and regulation through the proliferation and production of energy 
source [9, 10]. Oocytes have low glycolytic activity and preferentially utilise the 
provision of energy substrates from GCs by glucose uptake for energy homeostasis 
[11]. A dysregulation in these functions can lead to severe cellular damage, causing 
decreased rates of oocyte nuclear maturation and fertilisation [12–14]. Data from 
several studies suggest that GC dysfunction contributes to abnormal folliculogenesis 
in PCOS [15]. However, there are few reports on abnormal glycolysis. PCOS patients 
consistently suffer from sub-fertility or infertility, and the poor quality of oocytes may 
be the main cause. Studies have shown that oocytes have low glycolytic activity and 
glucose uptake through the surrounding cells; hence, GCs are vital for oocyte 
homeostasis. Furthermore, GC energy metabolic dysfunction affects oocyte 
maturation and contributes to abnormal folliculogenesis in PCOS [11]. 
 Glycolytic activity contributes to the cellular proliferation of GCs under hypoxic 
conditions during follicle maturation [16]. Hypoxia inducible factor-1α (HIF-α), 
which is the master regulator of cellular response to hypoxia, serves as a critical 
mediator of the adaptive response of tissue to low physiological oxygen levels. 
Previous reports have indicated that under hypoxia conditions, cells switch to the 
oxygen-independent metabolic pathway, and produce adenosine triphosphate (ATP) 
using the glycolysis pathway [17, 18]. This process is also essential for higher quality 
oocytes and embryonic development. Hypoxic conditions increase the expression of 
HIF-1 complex regulated genes and are associated with the activation of glycolysis 
and suppression of mitochondrial oxidative phosphorylation (OXPHOS), which lead 
to the induction of a metabolic switch from OXPHOS to glycolysis.  
 Metabolic disorders have been acknowledged as a frequent cause of classic PCOS 
[19]. It has been suggested that decreased mitochondrial O2 consumption and 
glutathione, together with increased reactive oxygen species (ROS), contribute to the 
mitochondrial dysfunction in PCOS patients [20]. In addition, the development 
potential of oocytes with low mtDNA copy numbers is significantly reduced, thereby 
reducing blastocyst formation, which is consistent with the common symptoms of 
PCOS patients, such as anovulation and infertility [21]. GC mitochondrial dysfunction 
also affects oocyte maturation and development in PCOS [20]. Furthermore, it has 
been shown that in patients with PCOS, elevated oxidative stress is involved in the 
pathophysiology of anovulation and is associated with hyperglycaemia and 
hyperandrogenaemia [20]. 
 All the above results lead to the hypothesis that maybe there is a relationship 
between the aberrant energy metabolism of GCs and PCOS-related abnormal follicles. 
Hence, the mitochondrial function and glycolytic activity, and the expression of HIF-α 
in patients with and without PCOS, who underwent IVF treatment, were compared in 
order to explore the relationship between the disorder’s metabolic switch and 
abnormal expression of HIF-α in aberrant follicles development. This is the first 
functional study of PCOS patient-derived GCs that has explored the abnormal 
mitochondrial activities and aberrant expression of glycolysis metabolic genes in 
GCs. 
 
Material and methods 
Subjects 
 The Ethics Committee of the Reproductive Centre of Shijiazhuang Obstetrics and 
Gynaecology Hospital approved the present study. In addition, written, informed 
consent was obtained from each patient. 
 Clinical data were retrospectively collected from PCOS patients and tubal factor 
infertility patients (non-PCOS) during their first cycle of in vitro fertilisation-embryo 
transfer (IVF-ET). A short-acting gonadotropin-releasing hormone agonist (GnRH-a) 
long protocol was employed in the pre-ovulatory phase at the Reproductive Centre of 
Shijiazhuang Obstetrics and Gynaecology Hospital between April 2018 and 
December 2018. A total of 60 patients with PCOS and 98 patients with tubal infertility 
were enrolled in the present study. The reproductive age ranged from 21 to 33 years.  
 The exclusion criteria were as follows:  
— diagnosis of PCOS according to the Rotterdam criteria of 2003: rare ovulation or 
anovulation (cycles longer than 35 days or shorter than 26 days); high androgen 
clinical manifestations or hyperandrogenism; polycystic ovaries (12 or fewer [2–9 
mm] follicles in each ovary identified by transvaginal ultrasonography); 
— compliance with at least two of the above and exclusion of other diseases causing 
related symptoms; 
— all non-PCOS patients had normal ovarian morphology and regular menstrual 
cycles with tubal factor infertility. 
 The exclusion criteria were as follows: autoimmune diseases; internal diseases; 
chromosomal abnormality; endocrine or metabolic diseases, including 
hyperprolactinaemia and endometriosis; uterine malformations; ovarian surgery or 
only one ovary; history of taking hormonal medicine in the past three months. 
 
Clinical tests and IVF cycle characteristics 
 The serum basal follicle-stimulating hormone (FSH), basal oestradiol (E2), basal 
luteinising hormone (LH), basal testosterone (T), fasting plasma glucose (FPG) levels 
on the second/third day of the menstrual cycle (follicular phase) after 12 hours of 
fasting, and the daily human chorionic gonadotropin (hCG) were measured at the 
Clinical Analysis Service of our hospital. 
 The characteristics of the IVF cycles included the following: total amount of 
administered FSH, days of using GnRH agonist, days of GN stimulation, total number 
of retrieved oocytes, number of MII oocytes, number of 2PN, overall fertilisation rate, 
high quality embryo rate, available embryo rate, high quality blastocyst formation rate, 
and clinical pregnancy rate.  
 
Human follicular fluid and GC preparation 
 Follicular fluid (FF) and mural granulosa cells (GCs) were collected, isolated, and 
pooled from PCOS and non-PCOS patients who underwent IVF-ET by controlled 
ovarian hyperstimulation (COH). The GnRH agonist (Ferring, Germany) was applied 
for approximately 18 days, when the downregulation standard was reached (FSH < 5 
mIU/mL, LH < 5 mIU/mL, E2 < 50 pg/mL, endometrial thickness < 5 mm), and Gn 
was subcutaneously injected until the hCG day. Then, cumulus-oocyte complexes 
(COCs) were retrieved from aspirated follicles 36 hours after the hCG trigger under 
transvaginal ultrasound guidance. After the COCs were removed from the follicular 
contents under a stereomicroscope using a Pasteur pipette, the follicular fluid was 
collected and centrifuged at 450 g for three minutes. Then, the clear supernatant was 
stored at –80°C for subsequent glucose, pyruvate, and OS level assessment. The GCs 
at the bottom of the Eppendorf tube were divided into two parts; one part was stored 
at –80°C for the detection of gene expression related to cell energy metabolism, while 
another part of the GCs was cultured for mitochondrial function and glycolysis 
analysis. Then, the oocytes were graded and subsequently inseminated. Pronuclear 
(PN) scoring was performed 16–18 hours after insemination. Embryo quality was 
assessed before every embryo transfer, and a maximum of three embryos were 
transferred to all patients at approximately 48 hours (four-cell stage) after 
insemination. 
 
Granulosa cells culture  
 The GCs were isolated and purified by Ficoll density gradient centrifugation 
combined with the attachment culture method. Briefly, GCs that precipitated at the 
bottom of the centrifugal pipe were re-suspended in 2 ml of phosphate-buffered saline 
(PBS) and centrifuged at 450 × g for three minutes to obtain a pellet. Then, these GCs 
were digested with trypsin-EDTA solution (Solarbio, Beijing, China), according to the 
manufacturer’s instructions. Subsequently, the cell suspensions were centrifuged at 
300 × g for three minutes, the supernatant was discarded, and GCs that precipitated at 
the bottom were re-suspended with 2 ml of PBS. Consequently, the cell suspension 
was slowly added to the Ficoll liquid surface and centrifuged at 300 × g for 15 
minutes. After centrifugation, these GCs were located at the interface between the 
upper mixed liquid and lower Ficoll liquid. Then, a pipette was used to gently absorb 
the cell layer. Afterwards, the solution was re-suspended with 2 ml of PBS and 
centrifuged at 300 × g for three minutes. Subsequently, the supernatant was poured 
out and a pellet was obtained. Next, the red blood cells (RBCs) were removed using 
erythrocyte lysis buffer. Then, 2 mL of lysis was added to the pellet in the tube and 
was gently shaken. After 20 seconds, the suspensions were centrifuged at 150 × g for 
three minutes. Then, the GC mass was resuspended in 3 ml of culture medium 
(DMEM/F12, 100 IU/mL of penicillin, 0.1 mg/mL of streptomycin and 10% foetal 
calf serum; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and transferred to a 
six-well culture dish (NEST, Shanghai, China) at approximately 2.5 × 105 cells/well 
for 24 hours at 37°C with maximum humidity, and under atmospheric conditions of 
5% CO2 and 95% air. After 24 hours, the whole solution was replaced, the unattached 
GCs were removed by gentle pipetting, and the morphology of the attached GCs were 
observed using an optical microscope and used for the experimental analysis. Cells 
were counted using a haemocytometer and seeded at densities of 2 × 104 cells/well in 
a 96-well culture dish for 24 hours. Then, these were exposed to carbonyl cyanide 
m-chlorophenyl hydrazine (CCCP,10 mM) and bromopyruvic acid (BA, 0.5 or 5.0 
mM), respectively, for further study. CCCP, which is a glycolysis inhibitor, and BA 
were diluted in DMSO (× 2000). Then, a control medium was added at the same 
concentration as that of the DMSO. 
 
Mitochondrial function assay 
Mitochondrial membrane potential (MMP) 
 A lipophilic cation, 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol 
carbocyanine iodide (JC-1), was used to assess the mitochondrial status in GCs. JC-1 
changes its fluorescence reversibly from green (monomeric status) to red (multimeric 
status) with the change in MMP. Furthermore, JC-1 is rapidly taken up by normal 
polarised mitochondria to form JC-1 aggregates, and presents a red spectral shift that 
results in increased levels of red fluorescence emission. In GCs of PCOS, the MMP 
collapses, and the JC-1 that accumulates within the mitochondria declines. In these 
cells, JC-1 remains in the cytoplasm in its monomeric form, and subsequently reduces 
the red fluorescence. Briefly, after culturing for 24 hours, the attached GCs from 
non-PCOS and PCOS were used to detect MMP using a Mitochondrial Membrane 
Potential Detection Kit (Solarbio, Beijing, China). GCs in 96-well plates were washed 
with PBS and incubated with JC-1 working solution at 37°C in a CO2 incubator for 20 
minutes. After rinsing twice with JC-1 staining solution, the MMP was monitored by a 
fluorescence spectrophotometer, and the relative MMP was calculated. After the GCs 
were attached, these were treated by the inhibitors of CCCP and BA at 20 minutes to 
detect MMP using the JC-1 Assay Kit mentioned above and a fluorescent microscope 
(Olympus, Tokyo, Japan). 
 
ATP content 
 The ATP content of GCs cultured for 24 hours and collected from the two groups 
was measured using a Firefly Luciferase-based ATP Kit (Beyotime, Nanjing, China), 
according to the manufacturer’s instructions. Briefly, GCs were cultured at 2 × 104 
cells/well in 96-well plates for 24 hours, lysed in ATP lysis buffer (from the kit), and 
centrifuged at 12,000 × g for 10 minutes. Then, the supernatants were mixed with the 
testing buffer, and the ATP concentrations were measured using a luminometer (the 
experiments were conducted in triplicate). After 20 minutes of treatment with CCCP 
and BA, inhibitor-treated GCs and control cells were used to test the ATP content with 
the kit, as previously described. 
 
Intracellular ROS production 
 The 2,7-dichlorofluorescin diacetate (DCFH-DA; Solarbio, Beijing, China) is a 
cell permeable peroxide-sensitive fluorescent probe used to detect intracellular free 
radicals. Once DCFH-DA enters into the cells and hydrolyses to dichlorofluorescin 
(DCFH) in the presence of free radicals such as H2O2, and peroxides, DCFH is 
oxidised to the green fluorescent product dichlorofluorescein (DCF) and trapped in 
the cell compartment, which can be measured by a fluorescence spectrophotometer. 
The wavelength of the laser was 488–525 nm (excitation and emission, respectively).  
 In the present study, two GC groups were collected and incubated with 
DCFH-DA at 37°C for 20 minutes. Then, fluorescent DCF were measured using a 
fluorescence spectrophotometer, and the relative absorbance values that characterise 
the ROS content were measured. At 30 minutes of CCCP and BA exposure, 
inhibitor-treated GCs and control cells were collected and incubated with DCFH-DA 
at 37°C for 20 minutes. Then, the ROS content was measured using a ROS Detection 
Kit. 
 
DNA extraction 
 Total DNA extraction from isolated GC fractions was carried out using a Tissue 
Genome DNA Extraction Kit (Germany, Shanghai, China), according to the 
manufacturer’s recommendations. Lysis was achieved by incubation of the sample 
material in a proteinase K solution. Appropriate conditions for DNA binding to the 
silica membrane in the centrifugal adsorption columns were obtained by the addition 
of chaotropic salts and ethanol to the lysate. The binding process was reversible and 
specific to nucleic acids. Contamination was removed by washing with two different 
buffers. The genomic DNA was finally eluted in 90 μL of elution buffer. 
 
Quantification of mtDNA 
 The mean mitochondrial DNA (mtDNA) copy number in GCs was determined by 
real-time quantitative PCR (Q-PCR) using the SYBR green DNA intercalator on the 
Chromo4 System® (Biorad, Hercules, CA, USA) in a 20 µL reaction volume, 
containing a final concentration of 0.4 µM of each gene-specific primer and 1 µl of 
template. The mitochondrial gene quantitative primers: ND1 forward 
5′-cctagccgtttactcaatcct-3′, and reverse, 5′-tgatggctagggtgacttcat-3′; nuclear gene 
primers: β-actin forward 5′-tggcacccagcacaatgaa-3′ and reverse 
5′-ctaagtcatagtccgcctagaagca-3′, as an internal control to quantitate the nuclear DNA 
in GCs. The reactions were performed as follows: initial denaturation at 95°C for 10 
minutes, and 40 cycles at 95°C for 45 seconds, 54°C for one minute, and 72°C for 45 
seconds. Each sample was run in triplicate. The level of mtDNA copy number was 
calculated using the delta Ct (∆Ct) of the average Ct of the mtDNA and nDNA (∆Ct = 
CtmtDNA -Ctβ-actin). The relative level of the mtDNA copy number was calculated 
using the 2-∆∆Ct method. 
 
Activity of oxidative stress markers in follicular fluid (FF)  
 The granulosa cells were isolated from all aspirated FFs in PCOS and non-PCOS 
patients using gradient centrifugation. The levels of malondialdehyde (MDA) and 
superoxide dismutase (SOD) in FF were respectively measured by thiobarbituric acid 
(TBA) and the chemiluminescence method. The 8-OHDG in FF was quantitatively 
detected by enzyme-linked immunosorbent assay (ELISA; Jiancheng, Nanjing, 
China). 
 
Glucose test assay 
 The glucose levels of FF in PCOS and non-PCOS patients were measured using a 
glucose assay kit (Jiancheng, Nanjing, China), according to the manufacturer’s 
protocol, before culture. After the GCs were attached, these were treated by the 
inhibitors of CCCP at 24, 48, and 72 hours. After exposure, cells were collected by 
centrifugation, and the supernatants were stored at –80°C for the glucose test. The 
samples were measured with a microplate reader at an absorbance of 505 nm. The 
tests were repeated three times, and the glucose consumption from the study group 
was calculated and compared to the cell-free original medium. 
 
Cell Counting Kit-8 (CCK-8) assay  
 The cellular proliferative activity of adherent GCs treated by the inhibitors of 
CCCP and cultured for 24, 48, and 72 hours was examined using a CCK-8 kit 
(Shanghai, Beyotime, China), according to the manufacturer’s instructions, in a 
96-well plate. The assay was repeated three times. 
 
Pyruvate production assay 
 The pyruvate concentrations of FF in PCOS and non-PCOS patients were 
measured at an absorbance of 450 nm, according to manufacturer’s protocol 
(Jiancheng, Nanjing, China). The experiments were conducted in triplicate. 
 
Real-time reverse transcript polymerase chain reaction (RT-PCR) 
 Total RNA was extracted from GCs in the non-PCOS and PCOS group using 
TRIzol (Solarbio, Beijing, China). Then, the complementary DNA (cDNA) was 
synthesised using a RevertAid First Strand cDNA Synthesis Kit (Jierui, Shanghai, 
China). The mRNA expression of GLUT1/LDHA/PFKP and HIF-1a was measured by 
real-time RT-PCR using the Power SYBR@ Green PCR Master Mix (Jierui, Shanghai, 
China) and normalised by the expression of the β-actin gene. The primers were 
selected according to previous reports, which were as follows: GLUT1 forward, 
5'-ccagctgccattgccgtt-3’and reverse 5'-gacgtagggaccacacagttgc-3'; LDHA forward, 
5’-tgcacccagatttagggactgat-3’ and reverse 5’-cccaggatgtgtagcctttgag-3’; PFKP 
forward 5’-aggcgatggacgagaggagat-3’and reverse 5’-tgatggcaagtcgcttgtag-3’; HIF-1α 
forward 5'-catcagctatttgcgtgtgagga-3' and reverse 5'-agcaattcatctgtgctttcatgtc-3'. The 
specificity of these primers was validated by dissociation curve analysis. The relative 
mRNA levels were expressed as 2-∆∆Ct values. 
 
Statistical analysis 
 Data are presented as mean ± standard deviation. Statistical differences were 
analysed via t-test for the two groups, and one-way analysis was performed to analyse 
three or more groups. Analyses were performed using GraphPad Prism software 
version 5 (GraphPad software, San Diego, CA). p < 0.05 was considered statistically 
significant. 
 
 
Results 
Characterisation of the clinical IVF cycle  
 A total of 158 patients who underwent 158 periods of COH were enrolled in the 
present study. There were no significant differences in the patients’ age or duration of 
infertility in these two groups. The discrepancy of endocrine and biochemical 
indicators accorded with the characteristic performance of PCOS. The levels of serum 
LH, P and T, the FBG, and the AFC were significantly higher in the PCOS group than 
in the non-PCOS group. However, on the premise of the consistency of COH schemes, 
and under the same Gn dosage and usage time, the number of retrieved oocytes in the 
PCOS group was significantly higher than that in the non-PCOS group. Nonetheless, 
the rate used for judging the quality of the embryo and its subsequent development 
viability, including the high-quality embryo rate, available embryo rate, and 
high-quality blastocyst formation rate, obviously decreased in PCOS (p < 0.01). In 
comparing the available embryo rate of IVF, it was found that embryos originating 
from PCOS had a significantly poorer developing competence, with a rate of 43.81%, 
while 58.72% of non-PCOS embryos could develop to available embryos before 
embryo transplantation. The general information and specific data on the outcome of 
IVF-ET in these two groups are presented in Table 1 and 2.  
 
Mitochondrial membrane potential 
 In the present study, GCs were collected from matured follicles of non-PCOS and 
PCOS ovaries undergoing ovarian stimulation for IVF, and the MMP was compared 
between these two groups. As shown in Figure 1, the MMPs of GCs were analysed 
using image-based cytometry. The MMP of GCs was significantly lower in PCOS, 
when compared to non-PCOS (1.073 ± 0.09 vs. 0.785 ± 0.04). In the cultured GCs, 
and in the treatment with mitochondrial inhibitors (CCCP, 10 µM) and glycolysis 
inhibitor (BA, 0.5 mM/2.5 mM), all had a significant effect on MMP. The intensity of 
red fluorescence gradually decreased, and the green intensity gradually increased. 
Finally, the relative values of MMP declined (control, 1.094 ± 0.12; CCCP, 0.476 ± 
0.07; BA 0.5 mM, 0.508 ± 0.18; BA 2.5 mM, 0.476 ± 0.13). The results confirm the 
reduction of red to green fluorescence by approximately one-half in response to 10 
µM of CCCP. Therefore, 10 µM of CCCP was used as the standard concentration in 
all further studies (N = 3, separate experiments).  
 As shown in Figure 2, the fluorescence microscopy revealed that the green 
fluorescence intensity in GCs increased when GCs were treated with mitochondrial 
inhibitors and the glycolysis inhibitor, while the red fluorescence intensity diminished. 
In addition, the intensity of green fluorescence in CCCP-treated GCs was the most 
obvious, when compared to those treated with BA (N = 3, in separate experiments). 
 
ATP content 
 As shown in Figure 3, the ATP content of GCs was significantly lower in PCOS 
than in non-PCOS (2.484 ± 0.03 µm vs. 3.916 ± 0.09 µm). In addition, after the 
treatment of GCs with mitochondrial inhibitor CCCP and glycolysis inhibitor BA, the 
ATP content was significantly reduced in all GCs (control, 8.775 ± 0.28 µm; CCCP 10 
µM, 8.116 ± 0.33 µm; BA 0.5 mM, 1.863 ± 0.27 µm; BA 2.5 mM, 0.482 ± 0.16 µm; p 
< 0.05). Furthermore, the glycolysis inhibitor had a more pronounced inhibition effect 
on GCs, when compared with mitochondrial inhibitors, and the inhibitory effect of 
BA 2.5 mM was stronger than that of BA 0.5 mM. Furthermore, the mitochondrial 
respiratory chain played critical roles in cell function and energy metabolism, while 
the glycolysis had the same or even stronger effect in the energy metabolism of GCs.  
 
Reactive oxygen species levels 
 Compared with the non-PCOS group, the ROS levels of GCs obtained from 
PCOS significantly increased (1.9-fold). The investigators previously reported that 
CCCP (10 µM) and BA (0.5 mM/2.5 mM) both affect mitochondrial function in GCs 
and induce the decrease of MMP and ATP content. Meanwhile, the intracellular ROS 
generation in GCs increases, accompanied by the former decline tendency. 
Furthermore, 10 µM of CCCP and 0.5 mM of BA slightly increased the ROS levels, 
but the difference was not statistically significant. The treatment with 2.5 mM of BA 
obviously enhanced the ROS level of GCs by 1.15-fold (p < 0.05, Fig. 4). Therefore, 
glycolysis not only plays a critical role in GC energy metabolism, but also influences 
mitochondrial oxidative metabolism.  
 
The mitochondrial DNA copy number in GCs and oxidative stress markers in FF 
 The relative mtDNA levels determined by real-time Q-PCR were significantly 
downregulated in GCs obtained from PCOS patients (1.021 ± 0.06 vs. 0.761 ± 0.05, p 
= 0.0018; Fig. 5A). Compared with the non-PCOS group, the levels of MDA, SOD, 
and 8-OHDG in FF detected via correlative experiment kits significantly increased, 
which was accompanied by a decrease in mtDNA level in PCOS patients (MDA, 
1.558 ± 0.10 vs. 2.047 ± 0.23 nmol/mL; SOD, 58.71 ± 3.13 vs. 71.17 ± 5.03 U/mL; 
8-OHDG, 0.7163 ± 0.06 vs. 0.9469 ± 0.10 ng/mL; Fig. 5B–D). The increase in 
peroxidation injuries that index MDA and 8-OHDG were accompanied by 
compensatory elevated antioxidant damage index SOD.  
 
Expression of the glycolysis-associated gene and HIF-1α in GCs, and glucose 
metabolism in FF 
 In order to determine whether the glycolysis-associated gene expression in GCs is 
correlated with follicle development, the GLUT1/LDHA/PFKP gene expression levels 
in non-PCOS and PCOS patients were measured. Compared to non-PCOS, the mRNA 
expression levels of GLUT1/LDHA/PFKP were significantly downregulated in GCs 
obtained from PCOS patients (GLUT1, 1.077 ± 0.10 vs. 0.734 ± 0.10; LDHA, 1.005 ± 
0.04 vs. 0.641 ± 0.1, PFKP, 1.103 ± 0.08 vs. 0.723 ± 0.10; Fig. 6A–C). Collectively, 
these data suggest that in ovarian PCOS, the expression levels of glycolytic 
rate-limiting enzymes in GCs were downregulated. 
 After GC isolation, the glucose levels in FF were measured, and the glucose 
uptake level was evaluated. Similar to the low expression pattern of the 
glycolysis-associated gene in GCs obtained from PCOS, the levels of elevated glucose 
(2.812 ± 0.33 vs. 5.505 ± 0.51 mmol/L, Fig. 6D) were accompanied by the levels of 
decreased pyruvate (0.2347 ± 0.03 vs. 0.1673 ± 0.01 µmol/mL, Fig. 6E). These results 
suggest that the downregulation of glycolysis-associated gene expression is a frequent 
occurrence in patients with PCOS, because the glycolysis dysfunction might impair 
the folliculogenesis in PCOS.  
 HIF-1α plays a key role in ovarian follicular development and ovulation. In order 
to determine whether the HIF-1α gene takes part in the pathophysiological changes in 
the ovaries of women with PCOS, the HIF-1α gene expression levels in non-PCOS 
and PCOS patients were measured. Compared to non-PCOS patients, the mRNA 
expression levels of HIF-1α were significantly reduced in GCs obtained from PCOS 
patients (1.141 ± 0.11 vs. 0.707 ± 0.09, Fig. 6F). HIF-1α can be largely increased in 
developing follicles, and the remarkable upregulation of HIF-1α triggers the cell 
glucose uptake. In the present study, consistent with the downregulated HIF-1α in 
GCs, the mRNA expression levels of GLUT1, LDHA, and PFKP decreased in GCs 
obtained from PCOS patients.  
 
CCCP-induced HIF-1α promotes glycolysis-associated gene expression and 
regulates glycolysis and cell viability 
 In order to further demonstrate the energy transformation function and 
mechanism in GCs under low oxygen conditions, the mitochondrial dysfunction 
model was applied. In the presence of 10 µM of CCCP in GCs, the mitochondrial 
respiratory chain was impaired, the oxygen-dependent degradation of HIF-1α was 
inhibited, and HIF-1α accumulation increased by 1.8-fold (Fig. 7A). Furthermore, the 
mRNA expression levels of GLUT1 and LDHA in GCs were upregulated, which in 
turn increased the glucose transport and uptake. In addition, GLUT1 was upregulated 
1.4-fold (Fig. 7B), while LDHA increased 1.2-fold (Fig. 7C). Consistent with the 
expression patterns of the HIF-1α, GLUT1, and LDHA genes, glucose consumption 
gradually increased after 24, 48, and 72 hours of culturing GCs after CCCP treatment, 
and the viability of cells tested by CCK-8 also increased (Fig. 8A–B, p < 0.05). These 
results suggest that ATP production via the mitochondria was inhibited, and switching 
of the energy metabolism to the glycolytic pathway was initiated. 
 
Discussion 
 In the present study, it was confirmed that there was excessive glucose in the 
follicle and serum obtained from patients with PCOS. In addition to the changes in 
biochemical indicators, decreased glycolysis activity, which was indicated by the 
reduced expression of PFKP, GLUT1, and LDHA, was also observed in GCs obtained 
from PCOS patients.  
 Animal studies on cows have demonstrated that the metabolic change from 
OXPHOS to glycolysis in folliculogenesis under low oxygen levels plays a key role in 
rapid GC proliferation [16]. In the present study, it was demonstrated that 
mitochondrial inhibitors and the glycolysis inhibitor jointly participated in GC energy 
factory works, and mitochondrial function, which included MMP and ATP levels, 
significantly declined, and this was accompanied by increased ROS production in 
GCs of PCOS. The source of excessive ROS generation in PCOS might be due to the 
impaired mitochondrial OXPHOS in GCs. It was also found that glycolysis not only 
plays a critical role in GC energy metabolism, but also influences mitochondrial 
oxidative metabolism.  
 Furthermore, it was also found the mitochondrial DNA (mtDNA) genes of GCs 
were downregulated in PCOS patients. It has been shown that the maintenance of the 
mtDNA copy number is essential for the preservation of mitochondrial function and 
cell growth. These results suggest that the copy number alteration of mitochondria 
DNA in GCs in PCOS patients were accompanied by mitochondrial oxidative injuries, 
thereby resulting in the higher MDA levels and 8-OHDG levels. Abnormal 
mitochondrial function at the cellular level can affect whole-body metabolic 
homeostasis [4]. A reduced mtDNA copy number is important for abnormal 
peroxidation and antioxidant status in FF of PCOS. These data are in line with 
previous studies, which revealed that OS level significantly increases in patients with 
PCOS, when compared with non-PCOS, when oxidative status is evaluated by 
circulating markers, such as malondialdehyde (MDA), superoxide dismutase (SOD), 
and glutathione peroxidase. Mitochondria play a vital role in cellular energy 
production and energy metabolism. The present study investigated the mitochondrial 
function and glycolysis activity in PCOS patient-derived GCs, and it was considered 
that the low expression of mtDNA and low expression levels of HIF1-α, GLUT1, 
LDHA and PFKP are causal factors of the suboptimal conditions for the process of 
GC differentiation during follicle development, which in turn affects oocyte 
maturation and induces abnormal oocyte quality and embryonic development. GC 
manifest two energy metabolism pathways during the late stage of follicle 
development and maturation, and the glycolysis has a greater impact on the growth of 
follicles. 
 The decreased mtDNA content in peripheral leukocytes was associated with the 
development of type 2 diabetes mellitus. However, it remains unclear whether 
mitochondrial abnormalities are a primary defect in the energy change of PCOS. In 
order to explore the mechanisms underlying the pathogenesis of metabolic changes in 
GCs, the role of mitochondrial inhibitor CCCP on energy metabolism of GCs was 
explored. After the CCCP treatment, the mitochondrial respiratory chains were 
impaired, and the balance of oxygen pressure in the follicle microenvironment was 
broken, which in turn stimulated HIF-1α, GLUT1, LDHA, and PFKP expression, 
promoted glucose consumption, and increased the viability of GCs. In PCOS patients, 
the damaged mitochondrial function and glycolysis showed that abnormal energy 
metabolic not only affects GC proliferation, but may also disturb the metabolic switch 
of energy from OXPHOS to glycolysis in GCs during follicle growth and 
development. Specifically, the reduction of mitochondrial activity in PCOS might 
inhibit the HIF-1a signalling, thereby further retarding the switch of energy 
metabolism during follicular growth. These results suggest that the downregulation of 
glycolysis-associated gene expression is a frequent occurrence in patients with PCOS, 
because glycolysis dysfunction might impair folliculogenesis in PCOS. Furthermore, 
on the basis of comparing the gene expression between non-PCOS and PCOS in 
matured GCs, it was considered that low expression levels of GLUT1, LDHA, and 
PFKP in PCOS patients could be considered as causal factors of sub-optimal 
conditions for GC differentiation during follicle development, which in turn affects 
oocyte maturation. The reduced expression levels of HIF-1α might be responsible for 
the downregulation of glycolysis in GCs in PCOS patients.  
 After the application of glycolytic inhibitors, the MMP and ATP of GCs 
significantly declined. However, in the presence of mitochondrial inhibitors, the 
glucose transport and uptake-associated gene expression increased. These results 
prove that the energy status of GCs was maintained by both the mitochondrial 
oxidative respiratory chain and glycolysis. In the presence of CCCP, the expression 
levels of HIF-1α and GLUT1, LDHA, and PFKP in GCs were upregulated. 
Meanwhile, the glucose consumption and viability of cells was gradually elevated. 
These data suggest that under hypoxia conditions the normal mitochondrial function 
was ensured, and the adaptive transformation of metabolism pattern may exist and 
play an important part in follicular development. ATP production via the mitochondria 
was inhibited, and the switching energy metabolism to the glycolytic pathway was 
initiated. This transformation promotes cell viability. In summary, it was demonstrated 
that in PCOS, mitochondrial dysfunction not only affects the energy state of GCs, but 
also inhibits the energy metabolic switch from mitochondrial to glycolysis 
metabolism.  
 
Conclusion 
 The present study revealed that abnormal mitochondrial function and disordered 
metabolic transformation from OXPHOS to glycolysis can be identified during 
folliculogenesis in PCOS patients. The failed switch of energy status can be attributed 
to the mitochondrial dysfunction of GCs. The improvement of mitochondrial 
respiratory function and glucose metabolism might enhance the competence of the 
embryo from PCOS. Further studies would be conducted on the important role of the 
HIF pathway in follicular development, which mainly depends on the normal 
mitochondrial function in GCs.  
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Table 1. Comparison of patients’ characteristics in both groups (x ± s) 
Parameters Control PCOS p value 
Number of cases 68 39  
Age [years] 29.46 ± 0.3484 28.59 ± 0.4884 0.1452 
BMI [kg/m2] 22.45 ± 0.4306 26.09 ± 0.5643 < 0.0001**** 
Duration of infertility [years] 3.5 ± 1.8 3.4± 1.0 0.99 
Antral follicle    
base-FSH [mIU/mL] 5.538 ± 0.2688 4.704 ± 0.1717 0.0284* 
base-LH [mIU/mL] 3.800 ± 0.2716 7.003 ± 0.4948 < 0.0001**** 
base-E2 [pmol/L] 34.64 ± 2.497 36.53 ± 2.697 0.6157 
base-P [nmol/L] 0.9115 ± 0.3740 0.8062 ± 0.5196 0.8681 
base-T [nmol/L] 0.9838 ± 0.03860 1.406 ± 0.1080 < 0.0001**** 
FPG 5.096 ± 0.05803 5.486 ± 0.2124 0.031* 
BMI — body mass index; FSH — follicle-stimulating hormone; E2 — oestradiol; LH — 
luteinising hormone; T — testosterone; FPG — fasting plasma glucose 
 
 
Table 2. In vitro fertilisation (IVF) outcome parameters in both groups (x ± s) 
Parameters Control PCOS p value 
Days of Gn 13.03 ± 0.2583 12.90 ± 0.4265 0.7792 
Total dosage of Gn [IU] 2753 ± 115.7 2654 ± 188.0 0.6349 
Days of HMG 7.000 ± 0.5951 4.880 ± 0.6666 0.0268* 
Days of GNRH-a 17.67 ± 0.3563 19.07 ± 0.6676 0.0454* 
E2 on hCG [pmol/L] 3481 ± 146.4 3457 ± 203.1 0.9222 
Retrieved oocytes 13.74 ± 0.6395 15.92 ± 0.8827 0.0447* 
Number of MII 12.59 ± 0.5716 14.49 ± 0.8271 0.0555 
2PN of fertilisation 10.01 ± 0.4659 11.51 ± 0.7160 0.0705 
Top quality embryos 5.118 ± 0.3290 5.154 ± 0.5084 0.9504 
Available embryos 6.971 ± 0.3875 7.026 ± 0.5685 0.9345 
Fertilisation rate (%) 72.91 72.30 0.8163 
High quality embryos rate (%) 51.40 45.07 0.0383* 
Available embryos rate (%) 58.45 50.37 0.0038** 
High quality blastocyst 
formation rate (%) 
14.18 10.09 0.0434* 
Clinical pregnancy rate (%) 77.14 38.46 0.0176* 
chorionic gonadotropin E2 — oestradiol; hCG— human chorionic gonadotropin; HMG — 
human menopausal gonadotropin; GnRH-a — gonadotropin-releasing hormone agonist; 2PN 
— two-pronuclear zygote; MII — metaphase II oocytes 
 
 
Figure 1. Mitochondrial membrane potential (MMP) in human granulosa cells (GCs) 
from patients without polycystic ovary syndrome (non-PCOS) and patients with 
polycystic ovary syndrome (PCOS), and the following treatment with inhibitors of 
mitochondrial function or glycolysis activity — image-based cytometry: 
mitochondrial membrane potential (MMP) was measured by the relative values of red 
to green fluorescence, as determined. MMP in GCs was compared between 
non-PCOS and PCOS. B) GCs were treated with CCCP (10 µM), BA (0.5 mM/2.5 
mM) for 30 min, and MMP in GCs was then measured by the ratio of red to green 
fluorescence intensity. Bars represent average values ± SEM of MMP in 2  104 GCs. 
The t-test and one-way ANOVA were used for statistical analysis. a-b, p < 0.05.  
 
Figure 2. Mitochondrial membrane potential (MMP) in human granulosa cells (GCs) 
from patients without polycystic ovary syndrome (non-PCOS) and patients with 
polycystic ovary syndrome (PCOS), and the following treatment with inhibitors of 
mitochondrial function or glycolysis activity — fluorescence microscopy: GCs were 
treated with CCCP (10 µM), BA (0.5 mM/2.5 mM) for 30 min; as the MMP declined 
the intensity of red fluorescence decreased to green fluorescence 
  
Figure 3. Adenosine triphosphate (ATP) content in human granulosa cells (GCs) from 
patients without polycystic ovary syndrome (non-PCOS) and patients with polycystic 
ovary syndrome (PCOS), following the treatment with inhibitors of mitochondrial 
function or glycolysis activity. A. ATP content in GCs were compared between 
non-PCOS and PCOS. B. GCs were treated with CCCP (10 µM), BA (0.5 mM/2.5 
mM), or vehicle (DMSO, Control), respectively, for 30 min, and ATP content was 
then measured. Bars represent average values ± SEM of ATP content in 2  104 GCs. 
The t-test and one-way ANOVA were used for statistical analysis (a–d, p < 0.05) 
 
 
 
Figure 4. Amount of reactive oxygen species (ROS) in human granulosa cells (GCs) 
from patients without polycystic ovary syndrome (non-PCOS) and patients with 
polycystic ovary syndrome (PCOS), following the treatment with inhibitors of 
mitochondrial function or glycolysis activity. GCs were treated with CCCP (10 mM) 
and BA (0.5 mM/2.5 mM), respectively, for 30 min, and the amount of ROS was then 
measured by fluorescence spectrophotometer. Average fluorescence intensity of 
human GCs was defined as 1.0. Fluorescence intensity of ROS was normalised by 
control in 2  104GCs. The t-test and one-way ANOVA were used for statistical 
analysis (a–b, p < 0.05) 
 
Figure 5. The mitochondrial DNA (mtDNA) copy number in in human granulosa 
cells (GCs) and the status of peroxidation and antioxidant in FF from patients without 
polycystic ovary syndrome (non-PCOS) and patients with polycystic ovary syndrome 
(PCOS). A. The relative level of mtDNA copy number in GCs of PCOS and 
non-PCOS were measured by real-time qPCR. B–D. Imbalances of abnormal 
peroxidation and antioxidant status in follicular fluid (FF). The level of 
malondialdehyde (MDA), superoxide dismutase (SOD), and 
8-hydroxydeoxyguanosine (8-OHDG) in FF were detected via correlative experiment 
kits, respectively. Data are presented as mean ± SEM. The t-test was used for 
statistical analysis (*p < 0.05) 
 
 
 
Figure 6. The expression of glycolysis-associated gene and HIF-1α in granulosa cells 
(GCs) and glucose metabolism in follicular fluid (FF) from patients without 
polycystic ovary syndrome (non-PCOS) and patients with polycystic ovary syndrome 
(PCOS). A–D. The relative mRNA levels of GLUT1, LDHA, PFKP, and HIF-1α in 
GCs from PCOS and non-PCOS were measured by real-time qPCR. E–F. Abnormal 
glucose metabolism in follicular fluid (FF). Data are presented as mean ± SEM. 
Student’s t-test was used for statistical analysis (*p < 0.05)  
 
Figure 7. The expression of glycolysis-associated gene in human granulosa cells 
(GCs), following the treatment with inhibitors of mitochondrial function. A–C. The 
relative mRNA levels of HIF-1α, GLUT1, and LDHA in GCs treated with 10 µM 
carbonyl cyanide m-chlorophenyl hydrazine (CCCP) were measured by real-time 
qPCR. Data are presented as mean ± SEM. Student’s t-test was used for statistical 
analysis (*p < 0.05)  
 
Figure 8. The level of glucose consumption of human granulosa cells (GCs) and cell 
viability, following the treatment with inhibitors of mitochondrial function. A. The 
level of glucose consumption of GCs after 10 µM carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP) treatment at 24 h, 48 h, and 72 h time points was detected by 
glucose kit. B. Cell Counting Kit-8 (CCK8) confirmed the cell growth after 10 µM 
CCCP treatment at 24 h, 48 h, and 72 h time points. Data are presented as mean ± 
SEM. Student’s t-test was used for statistical analysis (*p < 0.05) 
 
